Omnicell, Inc. 10-Q Summary: Quarter Ended September 30, 2004
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Omnicell, Inc., covering the three and nine months ended September 30, 2004. Omnicell provides medication and supply dispensing systems, pharmacy automation, and supply chain solutions to healthcare facilities. The company operates primarily in the United States and Canada, with distribution in Europe, Asia, and Australia. As of October 31, 2004, there were 25,287,153 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2004 | 3 Months Ended Sep 30, 2003 | 9 Months Ended Sep 30, 2003 |
|---|---|---|---|---|
| Total Revenues | $32,734 | $89,770 | $26,359 | $73,575 |
| Gross Profit | $19,088 | $53,381 | $15,559 | $42,825 |
| Operating Income | $3,287 | $8,112 | $2,509 | $4,248 |
| Net Income | $3,256 | $7,983 | $2,327 | $4,064 |
| Diluted EPS | $0.12 | $0.29 | $0.09 | $0.17 |
| Cash & Equivalents (Sep 30, 2004) | $21,373 | |||
| Short-term Investments (Sep 30, 2004) | $11,210 | |||
| Product Backlog (Sep 30, 2004) | $49.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 24.2% year-over-year for the quarter and 22.0% for the nine-month period. Product revenues grew 26.5% (quarter) and 22.3% (nine months), driven by increased installations and larger average deal sizes.
- Profitability: Net income rose 40% for the quarter and 96% for the nine-month period compared to 2003. Operating margins improved to 10.0% for the quarter (from 9.5%) and 9.1% for the nine months (from 5.8%).
- Cash Flow: Net cash provided by operating activities turned negative at $(2.996) million for the nine months ended September 30, 2004, compared to $6.345 million provided in the prior year. This was primarily due to an $8.4 million increase in inventory and a $2.9 million increase in accounts receivable.
- Inventory Build-up: Inventories increased from $8.783 million to $17.197 million, attributed to building stock for expected customer orders anticipated to ship in the fourth quarter.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 23.4% for the quarter due to a 22% increase in headcount to support revenue growth.
Guidance, Outlook, and Risks
- Outlook: Management expects product revenues to experience modest growth for the remainder of 2004. Service revenues are expected to increase slightly. The company aims to maintain gross profit margins at current levels.
- Backlog Strategy: The company is actively reducing reliance on "turns" business (orders installed in the same quarter) to improve predictability. Product backlog increased by $3.3 million in the quarter to $49.7 million.
- Liquidity: Total liquidity (cash, equivalents, and short-term investments) was approximately $32.6 million. Management believes current cash balances are sufficient for the next 12 months but has filed a Form S-3 registration statement to raise up to $100 million if needed.
- Risks:
- Installation Delays: Revenue recognition is tied to installation, which can be delayed by customer budget cycles or complex integration requirements.
- Competition: Intense competition from larger entities like Pyxis (Cardinal Health) and McKesson Automation.
- Legal Proceedings: A lawsuit filed by ePlus Government Inc. seeks approximately $1.7 million regarding a customer's failure to pay on a receivable sold with recourse. Management believes no payment will be required, but litigation risks remain.
- Accounting Changes: The upcoming adoption of FASB Statement No. 123R (Share-Based Payment) is expected to have a material impact on future results, potentially reducing net income significantly (pro forma net income for the nine months would have been $2.0 million vs. reported $8.0 million).
Investor Verification Checklist
- Inventory Turnover: Verify the timing of the $8.4 million inventory build-up and confirm if the anticipated Q4 shipments materialize to prevent write-downs.
- Operating Cash Flow: Monitor the reversal of negative operating cash flow in subsequent quarters as inventory is converted to revenue.
- Legal Contingency: Track the status of the ePlus Government Inc. lawsuit to ensure no material liability is recognized.
- Stock-Based Compensation Impact: Assess the financial impact of the mandatory adoption of FASB 123R in 2005 on future earnings per share.
- Backlog Conversion: Confirm the conversion rate of the $49.7 million product backlog into recognized revenue in Q4 2004 and Q1 2005.